Progress of evidence-based treatment decision support utilizing Molecular Health Guide in patients with gynecological solid tumors over three to six years

Objective To evaluate whether the progress of biomarker knowledge and therapeutic options has resulted in different treatment recommendations generated by the, CE-marked in-vitro diagnostic device, MH Guide, for patients with gynecological solid tumors in 2020 compared to the period of 2014 to 2017.

Methods Patient tumor samples were sequenced either by a 613-gene panel or WEX analysis. Data were analyzed between 2014 and 2017 by MH Guide, a CE-marked IVD for treatment decision support, based on patient specific variants matched to published peer-reviewed clinical evidence contained in proprietary databases. Utilizing the same patient data, reports were re-analyzed in 2020.

Results Tumor data from 174 patients with gynecological solid tumors were analyzed by MH Guide at two independent time-points separated by at least a three-year interval. Predicted effective therapies, adverse events, ineffective therapies, and opportunities for clinical trial recruitment were identified and reported by MH Guide. Treatment recommendations increased based on the incremental gain in underlying biomedical knowledge. Detailed results will be provided at the conference.

Conclusions The number and complexity of treatment options for patients with gynecological tumors has increased over just three to six years. To ensure that patients will benefit from these increased treatment options in routine medical practice, technologies are required that efficiently assist with interpretation of clinico-molecular patient data against the rapidly advancing biomedical knowledge. This analysis highlights the importance of up-to-date predictive biomarker evidence for treatment recommendations in clinical routine, that can only be assured by CE-marked decision support platforms such as MH Guide.

Publication History

Article published online:
07 October 2020